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Edited by Laszlo NagyAbstract C-reactive protein (CRP) is elevated in cardiovascu-
lar disease and binds to oxidized phosphatidylcholine (oxPtC)
in the low-density lipoprotein (LDL) surface. In the present
study, we tested if CRP inﬂuences the susceptibility of LDL to
oxidation. At physiological concentrations of 1–7 lg/ml, CRP
strongly inhibited copper-mediated oxidation of LDL and
phospholipid liposomes in a concentration-dependent manner.
Similar concentrations of diﬀerent monoclonal antibodies or
albumin did not inﬂuence LDL oxidation. Antioxidant activity
of CRP was inhibited by phosphocholine (PC), indicating that
the observed activity involves binding of CRP to oxPtC. These
results suggest that CRP may limit atherogenic oxidation of
LDL in vivo.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Conjugated dienes1. Introduction
C-reactive protein (CRP) is an acute phase reactant that is
upregulated by microbial infections [1,2]. The protein consists
of ﬁve identical subunits, each with a single binding site for
phosphocholine (PC) [3]. Binding of CRP to the PC compo-
nent of surface polysaccharides opsonizes invading microbes,
leading to enhanced uptake of these microbes by phagocytic
cells of the immune system. CRP binds to Fc-gamma-receptors
[4–6] and to C1q [7], causing activation of the complement
pathway. Thus, CRP serves as a critical component of the in-
nate immune system.
Recent studies have shown that CRP also binds to the PC
moiety of oxidized phosphatidylcholine (oxPtC) in the surface
of apoptotic cells and oxidized LDL [8]. CRP does not bind to
viable cells or non-oxidized LDL, in which the PC head groups
of phosphatidylcholines are thought to be cryptic [8]. The
oxPtC ligand of CRP is similar, if not identical, to the ligand
of anti-PC auto-antibodies and to ligands of the macrophage
scavenger receptors, CD36 and SR-B1. Hence, oxPtC appearsAbbreviations: CRP, C-reactive protein; oxPtC, oxidized phos-
patidylcholine; LDL, low-density lipoprotein; PC, phosphocholine;
apoB, apolipoprotein B-100; SAPtC, 1-stearoyl 2-arachidonyl phos-
phatidylcholine
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doi:10.1016/j.febslet.2006.08.045to be a pattern recognition ligand that interacts with multiple
pathways of the innate immune system [9]. Growing evidence
suggests that these pathways have evolved to dispose of dam-
aged molecular complexes, such as apoptotic cells and oxidized
LDL [9].
The clearance of damaged, oxidized LDL is intimately tied
to the development and progression of atherosclerosis [10].
Oxidation of LDL in the vascular intima generates a variety
of bioactive lipids that induce the recruitment and diﬀerentia-
tion of macrophages. These macrophages take up and neutral-
ize oxidized LDL by scavenger receptor-mediated endocytosis,
a process that may lead to the formation of foam cells, athero-
sclerotic plaques, and subsequent cardiovascular events. Thus,
oxidized LDL has been identiﬁed as a major factor in the
development and progression of atherosclerosis [10]. Likewise,
CRP, which binds to the surface of oxidized LDL, has been
linked to cardiovascular disease [11–14]. The plasma concen-
tration of CRP correlates with the risk of myocardial infarc-
tion and stroke, and has recently emerged as a sensitive risk
marker for cardiovascular events [13,14].
It is currently unclear if CRP plays an active role in the car-
diovascular disease process [15,16]. Although early in vitro
experiments have suggested that CRP itself is pro-atherogenic
[17–20], recent studies indicate that many of the observed ath-
erogenic events were induced by trace amounts of azide in the
CRP preparation and not by CRP itself [21–24]. Furthermore,
overexpression of human CRP in apolipoprotein E-deﬁcient
mice did not accelerate the development or progression of ath-
erosclerosis [25]. Hence, a clear pro- or anti-atherogenic role of
CRP remains to be established.
As CRP binds to oxPtC in the surface of oxidized LDL [8],
and oxPtC-intermediates participate in oxidative chain reac-
tions [26], we hypothesized that the binding of CRP to oxi-
dized LDL may inﬂuence further oxidation of the
lipoprotein particle. To test this hypothesis, we monitored
the in vitro oxidation of LDL in the presence or absence of
CRP. Our results demonstrate that physiological concentra-
tions of CRP inhibit LDL oxidation, suggesting that the pro-
tein may limit the atherogenic oxidation of LDL in vivo.2. Materials and methods
2.1. Materials
Human CRP (>99% pure) was obtained fromMP Biomedicals, LLC
(Solon, OH). Bovine serum albumin (BSA), phosphocholine (PC), and
monoclonal anti-PC antibodies (TEPC15) were purchased from Sigma
Chemical Company (St. Louis, MO). Monoclonal antibodies against
apolipoprotein B-100 (apoB) were purchased from Calbiochem (La
Jolla, CA); 1-stearoyl-2-arachidonyl phosphatidylcholine (SAPtC)
was obtained from Avanti Polar Lipids Inc. (Alabaster, AL).blished by Elsevier B.V. All rights reserved.
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LDL (d = 1.019–1.063 g/mL) was isolated from the blood of normo-
lipidemic subjects using sequential ﬂoatation ultracentrifugation [27],
essentially as described by Schumaker and Puppione [28]. Puriﬁed
LDL was dialyzed against phosphate-buﬀered saline (PBS) (i.e.,
10 mM sodium phosphate, 150 mMNaCl, pH 7.4), stored under argon,
and used within 7 days. Blood samples for LDL isolation were donated
with informed consent under protocols that were approved by the Insti-
tutional Review Board of Virginia Commonwealth University.
2.3. Oxidation of LDL
Oxidation reactions were performed at 37 C in 1 ml volumes of
PBS, 0.5 mM CaCl2, pH 7.4, and with puriﬁed LDL at a concentration
of 50 lg protein/ml. Oxidation of LDL was catalyzed with 2 lMFig. 1. CRP inhibits copper-mediated oxidation of LDL in a concentration-d
was catalyzed with 2 lM CuCl2. Data points represent single measurements.
oxidation lag time, a decrease in maximum oxidation rate, and an increase in
from diﬀerent donors, oxidized in the absence (closed symbols) and presence (
shape refer to LDL from the same donor. (C) Triplicate incubations of a s
presence (open symbols) of 4 lg/ml CRP. (D) BSA, at concentrations of 10 a
Monoclonal antibodies against apoB (a-apoB) and phosphorylcholine (TEP
inhibits the formation of TBARS (open symbols), as well as conjugated d
additional protein; squares: control incubations in the presence of 7 lg/ml BCuCl2. Susceptibility of LDL to oxidation was determined by spectro-
photometric detection of conjugated dienes at 234 nm, as described by
Esterbauer et al. [29], by spectrophotometric detection of thiobarbitu-
ric acid-reactive substances (TBARS), as described by Morel et al. [30],
and by determining the relative electrophoretic mobility of oxidized
LDL in agarose gels.
Formation of conjugated dienes was monitored in quartz cuvettes,
using a Lambda 20 spectrophotometer (Perkin–Elmer Corp., Norwalk,
CT). The temperature of the cuvettes was maintained at 37 C using a
PTP-1 Peltier System (Perkin–Elmer Corp.). Background absorbance
of PBS (containing 2 lM CuCl2, and in some cases CRP, BSA, mono-
clonal antibodies, or PC) was adjusted to 0, after which LDL was
added to start the oxidation reactions. Initial absorbance of unoxidized
LDL (50 lg protein/ml) was between 0.2 and 0.3 AU. In experimentsependent manner. In panels A–F, oxidation of LDL (50 lg protein/ml)
(A) Concentrations of 1–7 lg/ml CRP caused a progressive increase in
time to reach maximum oxidation (see Table 1). (B) LDL preparations
open symbols) of 4 lg/ml CRP. Open and closed symbols with the same
ingle LDL preparation, oxidized in the absence (closed symbols) and
nd 20 lg/ml, had no inﬂuence on copper-mediated LDL oxidation. (E)
C15) had no inﬂuence on copper-mediated LDL oxidation. (F) CRP
ienes (closed symbols). Circles: control incubations in the absence of
SA; triangles: incubations in the presence of 7 lg/ml CRP.
Fig. 2. CRP inhibits the formation of negatively charged LDL.
Oxidation of LDL (50 lg protein/ml) was catalyzed for 2 h at 37 C
with 2 lM CuCl2. Copper-mediated oxidation increased the negative
charge and electrophoretic mobility of LDL in 0.5% agarose gels (lanes
1 and 2). CRP (7 lg/ml) prevented the formation of negative charges
and the increase in electrophoretic mobility (lane 4), while 7 lg/ml BSA
did not (lane 3).
M.L. Rufail et al. / FEBS Letters 580 (2006) 5155–5160 5157addressing the inﬂuence of PC on CRP antioxidant activity, CRP was
pre-incubated with PC for 1 h at 37 C (in PBS) before oxidation was
started by the addition of 2 lM CuCl2 and 50 lg/ml LDL.
For TBARS assays, 500 ll of 20% trichloracetic acid (TCA) were
added to a 50 ll aliquot of LDL (50 lg/ml), either before or after oxi-
dation in the presence or absence of BSA or CRP as described above.
Samples with TCA were placed on ice for 5 min. After precipitation,
500 ll of a 1% thiobarbituric acid solution were added, and the sam-
ples were heated at 95 C for 45 min, cooled down on ice for another
5 min, and centrifuged at 1000 · g for 20 min. Subsequently, the absor-
bance of the supernatant was measured at 532 nm.
Increased negative charge and electrophoretic mobility of oxidized
LDL, were determined in 0.5% agarose gels. LDL (3 lg protein in
a 10 ll sample) was subjected to electrophoresis for 30 min at 100 V
in 0.1 M Tris-base, 0.09 M boric acid, 1 mM EDTA, pH 8.3. LDL
was ﬁxed and stained in the gel with glacial acetic acid:water:methanol
(1:3:6), containing 7% Sudan Black.
2.4. Oxidation of phospholipid liposomes
SAPtC liposomes were prepared essentially as described by Baren-
holz et al. [31]. Brieﬂy, 20 mg of SAPtC were dried under argon and
subsequently subjected to vacuum for 2 h at 20 C. Lipids were then
resuspended in 2.4 ml of PBS, and soniﬁed using a model 450 soniﬁer
(Branson Ultrasonics Corp., Danbury, CT) in cycles of 2–3 min for not
more than 30 min. The preparation was kept on ice for 1 min between
cycles. The soniﬁer output control was set at 2 and the duty cycle was
set at 30%. The resulting liposome suspension was subjected to centri-
fugation at 14000 r.p.m. for 12 min in an Eppendorf microcentrifuge.
The supernatant, containing a more homogeneous liposome disper-
sion, was collected and assayed for phospholipid content using a
spectrophotometric assay (Wako chemicals, Neuss, Germany).
Copper-mediated oxidation of the liposome preparation was per-
formed as described above for LDL, using 100 lg/ml of phospholipid
and 2 lM CuCl2 per sample.3. Results
Fig. 1A and Table 1 show that CRP inhibits copper-medi-
ated oxidation of LDL in a concentration-dependent manner,
as measured by the formation of conjugated dienes. Physiolog-
ical concentrations of 1–7 lg/ml CRP caused an increase in
oxidation lag time, a decrease in maximum oxidation rate,
and an increase in the time it takes to reach maximum levels
of oxidation (Fig. 1A and Table 1). At a concentration of
7 lg/ml CRP, oxidation of LDL was dramatically reduced,
and establishment of a typical oxidative propagation phase
was completely prevented within the 350 min experimental
timeframe.
The experiment of Fig. 1A was repeated multiple times with
LDL preparations from diﬀerent donors. Each of these exper-
iments conﬁrmed the dose-dependent antioxidant activity of
CRP, and in each of the experiments a concentration of
7 lg/ml CRP prevented establishment of a propagation phase
within the experimental timeframe (350 min). However, anti-Table 1
Inﬂuence of CRP on LDL oxidation
[CRP]
(lg/ml)
Lag time
(min)
Maximum
oxidation rate (E234 nm/min)
0 22 0.0149
3 41 0.0107
5 75 0.0060
7 ND 0.0006
Quantitative parameters were derived from the oxidation curves of Fig. 1A.
steepest part of the oxidation curve; Lag time [29]: time point at which a straig
a horizontal line through the starting value of conjugated dienes (E234 nm
experimental time-frame.oxidant kinetics of CRP concentrations lower than 7 lg/ml
varied when assayed with LDL preparations from diﬀerent do-
nors (Fig. 1B). Among the three LDL samples of Fig. 1B, the
increase in lag time due to the inclusion of 4 lg/ml CRP varied
from 253% to 412%, the decrease in maximum oxidation rate
varied from 32% to 42%, and the increase in the time it took
to reach maximum levels of oxidation varied from 205% to
396%. When assayed on a single LDL sample, oxidative
parameters were very reproducible, both in the absence and
presence of CRP (Fig. 1C); standard deviations for the tripli-
cate measurements in Fig. 1C ranged from 0.006 to 0.055
absorbance units.
In contrast to the strong antioxidant activity of 1–7 lg/ml
CRP (Fig. 1A), BSA at concentrations of up to 20 lg/ml
(Fig. 1D) and anti-apoB or anti-PC monoclonal antibodies
at concentrations of 10 lg/ml (Fig. 1E) did not aﬀect LDL oxi-
dation. Fig. 1F shows that CRP but not BSA prevented the
time-dependent formation of both conjugated dienes and
TBARS when LDL was incubated with 2 lM CuCl2. Simi-
larly, CRP but not BSA prevented the formation of negative
charges on the lipoprotein particle upon incubation with
2 lM CuCl2 (Fig. 2).
To test whether the antioxidant activity of CRP requires the
presence of apolipoprotein B-100 (apoB), i.e., the major protein
component of LDL, we assessed the oxidation of protein-free
SAPtC liposomes. Fig. 3 shows that, in the absence of CRP,
copper-mediated oxidation of 100 lg/ml SAPtC does not have
a well-deﬁned lag phase. Instead, oxidation immediately enters
the propagation phase and proceeds at a relatively constant
rate until a maximum oxidation level is reached after approxi-
mately 550 min. In the presence of 2–6 lg/ml CRP, oxidation
rates decreased in a concentration-dependent manner, and
maximum oxidation levels were not reached within the
600 min experimental timeframe (Fig. 3A). At a CRP concen-Time to oxidation
maximum (min)
Oxidation maximum
(E234 nm)
90 1.074
135 1.071
270 1.087
ND ND
Maximum rate of oxidation [29]: slope of a straight line through the
ht line through the steepest part of the curve (maximum rate) intersects
) in the sample (see Fig. 1A). ND: cannot be determined within the
Fig. 3. CRP inhibits copper-mediated oxidation of SAPtC liposomes
in a concentration-dependent manner. Oxidation of SAPtC (100 lg/
ml) was catalyzed with 2 lM CuCl2. (A) Concentrations of 1–6 lg/ml
CRP caused a progressive decrease in maximum oxidation rate, and an
increase in time to reach maximum oxidation. (B) BSA, at concentra-
tions of 10 and 20 lg/ml, had no inﬂuence on copper-mediated
oxidation of liposomes. (C) Monoclonal antibodies against apoB (a-
apoB) or phosphorylcholine (TEPC15) had no inﬂuence on copper-
mediated oxidation of liposomes. Data points in A–C represent single
measurements; experiments were repeated at least 3 times with similar
results.
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SAPtC oxidation was completely inhibited. In contrast, BSA
at concentrations of up to 20 lg/ml (Fig. 3B) and anti-apoB
or anti-PC monoclonal antibodies at concentrations of 10 lg/
ml (Fig. 3C) did not aﬀect SAPtC liposome oxidation. Hence,
the concentration-dependent antioxidant activity of CRP does
not require the presence of apoB or any other protein.
To further address the biochemical mechanism of the ob-
served antioxidant activity, we oxidized LDL in the absence
or presence of PC, which is a competitive inhibitor for the
binding of CRP to oxPtC. In the absence of PC, 5 lg/mlCRP strongly inhibited LDL oxidation (Fig. 4). However, a
25 lM concentration of PC strongly attenuated the inhibition,
as evidenced by a decreased oxidation lag time, an increased
maximum rate of oxidation, and a decreased time to reach
the maximum level of oxidation (Fig. 4 and Table 2). Higher
concentrations of PC (up to 100 lM), did not further inhibit
the antioxidant activity of CRP (results not shown). Control
incubations demonstrated that, in the absence of CRP, PC
does not inﬂuence LDL oxidation rates (Fig. 4). Taken to-
gether, these results suggest that the observed antioxidant
activity is speciﬁc and depends, at least in part, on the binding
of CRP to oxPtC head groups in the LDL surface.4. Discussion
Recent studies have shown that CRP is a sensitive risk mar-
ker for cardiovascular disease [13,14]. However, the precise
role of CRP in the development or progression of atheroscle-
rosis remains to be deﬁned. The present study shows that
CRP inhibits in vitro oxidation of LDL, suggesting that the
protein may limit the atherogenic oxidation of LDL in vivo.
The molecular mechanism that underlies the observed anti-
oxidant activity of CRP is unclear. However, the activity does
not appear to require apoB or any minor protein component
of LDL, as CRP also inhibits oxidation of a protein-free lipo-
some preparation (Fig. 3). Furthermore, inhibition of the
activity by PC (Fig. 4) suggests that CRP needs to interact with
oxPtC in the LDL surface in order to exert its antioxidant ef-
fect. This suggestion is consistent with recent studies describing
the binding of CRP to oxidized LDL [8]. The exact chemical
nature of the oxPtC ligand is unknown [8]. Indeed, CRP
may bind to a variety of oxPtC species, including reactive
oxPtC intermediates that are involved in oxidative chain reac-
tions, such as PtC-peroxiradicals and PtC-hydroperoxides [26].
Binding of CRP to these reactive oxPtC intermediates may
slow their lateral movement within the LDL surface and, as
a result, may limit further oxidative events. In addition, bind-
ing of CRP to reactive oxPtC species may shield these interme-
diates from interacting with unoxidized phospholipids,
likewise, limiting the progression of oxidative chain reactions.
The concentrations of CRP used in the present study to in-
hibit LDL oxidation (1–7 lg/ml) are within the range of phys-
iological concentrations that indicate increased cardiovascular
risk [11,13]. In subjects without microbial infection, plasma
CRP levels below 1 lg/ml indicate relatively low risk, while lev-
els of 1–3 lg/ml indicate moderate risk, and levels above 3 lg/
ml indicate high risk of cardiovascular disease [11,13]. The fact
that CRP concentrations of 1–7 lg/ml inhibit LDL oxidation
under aggressive in vitro conditions (Figs. 1 and 2) supports
the notion that similar concentrations of the protein may be
protective under milder in vivo conditions.
Consistent with an in vivo antioxidant role of CRP is the
protein’s localization in atherosclerotic lesions [32–34]. Recent
data show that vascular endothelial cells can be induced to ex-
press CRP [35], suggesting that the protein may be secreted di-
rectly into the extracellular environment in which LDL
oxidation occurs. It is, therefore, tempting to speculate that
mild oxidation of LDL induces the recruitment of CRP to
the lipoprotein surface in order to prevent further oxidation
of LDL, and to promote clearance of minimally oxidized lipo-
protein particles by macrophages and dendritic cells. This pro-
Fig. 4. PC inhibits the antioxidant activity of CRP. Oxidation of LDL (50 lg protein/ml) was catalyzed with 2 lM CuCl2. Copper-mediated
oxidation of LDL () was strongly inhibited by 5 lg/ml CRP (n), while 25 lM of PC () attenuated this inhibition. Data points represent single
measurements; experiments were repeated at least three times with similar results.
Table 2
Inﬂuence of PC on the antioxidant activity of CRP
[CRP] (lg/mL) [PC] (lM) Lag time (min) Maximum oxidation
rate (E234 nm/min)
Time to oxidation
maximum (min)
Oxidation
maximum (E234 nm)
0 0 28.5 0.01875 90 1.1461
0 100 28.5 0.02030 90 1.1360
5 0 139.5 0.00362 420 1.1162
5 25 64.5 0.00720 240 1.1795
Quantitative parameters were derived from the oxidation curves of Fig. 4. (For deﬁnition of ‘lag time’ and ‘maximum oxidation rate’, see Table 1.)
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excessive conditions lead to atherosclerosis. Thus, high plasma
concentrations of CRP, indicating high risk of cardiovascular
disease [13,14], may indicate maximal engagement of a protec-
tive mechanism.
Future studies will need to establish whether the observed
antioxidant activity of CRP indeed plays a signiﬁcant role in
cardiovascular disease and other inﬂammatory disorders.
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